C4X Discovery Holdings PLC is a biotechnology company with a strong emphasis on innovation and collaboration. With its core values centered around excellence, transparency, and integrity, C4X Discovery aims to revolutionize drug discovery and deliver breakthrough medicines for unmet medical needs. The company's corporate philosophy focuses on leveraging its proprietary technologies, such as Conformetrix and Taxonomy3, to accelerate the discovery of novel small molecules. By combining cutting-edge science with efficient drug development, C4X Discovery strives to create value for shareholders and contribute to the improvement of global healthcare outcomes.

C4X Discovery Holdings PLC is primarily present in the United Kingdom.

C4X Discovery Holdings PLC has achieved several significant milestones. The company successfully entered into multiple research collaborations with renowned pharmaceutical companies, which highlighted their expertise in novel drug discovery. They also forged partnerships with academic institutions and industry experts to boost their drug development capabilities. Additionally, C4X Discovery Holdings PLC successfully completed a funding round, raising substantial capital to support their research and development efforts. These milestones showcase the company's commitment to innovation and collaboration, positioning them as a prominent player in the drug discovery industry.

C4X Discovery Holdings PLC is a renowned biopharmaceutical company focused on developing innovative drugs for a range of diseases. Established in 2008, the company utilizes its proprietary technology platforms to discover potential drug candidates efficiently. C4X Discovery's innovative approaches, such as Conformetrix and Taxonomy3, enable the rapid identification and optimization of new drugs. With a strong emphasis on data-driven research, the company collaborates with global partners to advance drug development programs. C4X Discovery's commitment to scientific excellence and strategic partnerships positions them as a leader in the field of drug discovery, offering promising solutions for unmet medical needs.

The main competitors of C4X Discovery Holdings PLC in the market include other pharmaceutical and biotechnology companies. Some notable competitors are AstraZeneca, GlaxoSmithKline, Pfizer, and Novartis. These companies are also involved in drug discovery and development, utilizing various technologies and research approaches. As C4X Discovery Holdings PLC focuses on innovative drug discovery platforms, it faces competition within the pharmaceutical industry in terms of attracting investors, collaborating with research partners, and commercializing its discoveries. Nevertheless, C4X Discovery Holdings PLC continues to differentiate itself through its unique technologies and collaborations, positioning itself as a prominent player in the drug discovery market.

C4X Discovery Holdings PLC is primarily active in the pharmaceutical and biotechnology industries.

C4X Discovery Holdings PLC is a biotechnology company with a unique business model focused on drug discovery and development. Their core technology, known as Conformetrix, enables the structural analysis of drug targets and molecules. By identifying and validating potential drug candidates, C4X Discovery aims to partner with pharmaceutical companies to progress these candidates through preclinical and clinical development. With an emphasis on small molecule drugs for diseases with high unmet medical needs, C4X Discovery utilizes its innovative approach to accelerate the discovery of novel therapies.

C4X Discovery Holdings P/E suhe on 1,71.

C4X Discovery Holdings KUV on 0,99.

AlleAktien kvaliteediskoor ettevõttele C4X Discovery Holdings on 6/10.

oodatud C4X Discovery Holdings käive on 30,50 mln. GBP.

oodatud C4X Discovery Holdings kasum on 17,58 mln. GBP.

C4X Discovery Holdings PLC is a biopharmaceutical company specializing in the discovery and development of new drugs for diseases such as cancer, inflammation, neurological disorders, and infections. The company is headquartered in the United Kingdom and operates additional research facilities in the United States. The core business of C4X is innovative structure- and computer-based drug research. The company has a patented technology called "Conformetrix," which provides a unique approach to drug discovery. The proprietary technology allows C4X to analyze the three-dimensional structure of target proteins and develop medical drugs tailored to these foundations. C4X Discovery consists of three main areas: drug development, drug discovery, and data analysis. In the drug development area, C4X focuses on developing drugs for various diseases. The company is currently involved in the preclinical phase of four main projects: CXD101, a cancer drug, CXD201, an anti-inflammatory drug, CXD301, a drug for COPD, and CXD401, a drug for neurodegenerative diseases. In drug discovery, C4X develops new drugs for various applications. The company works closely with partners from various industries to optimize its results and make them commercially viable in various ways. In the data analysis area, C4X experts use specialized software to analyze and evaluate large amounts of data. This allows the company to identify patterns and trends and optimize its drug and drug development. C4X Discovery is a profitable company focused on long-term growth. In recent years, the company has entered into a number of key partnerships to advance its research and development. In 2018, C4X announced a collaboration with Indivior PLC to develop new drugs for opioid dependence. In the same year, the company also completed a research collaboration with the University of Kansas related to the development of new cancer drugs. C4X Discovery also uses its technology to develop drugs from third-party companies. As part of research and development partnerships, the company seeks solutions to support its partners by developing specialized constructs and procedures to optimize processes. This approach has helped C4X in the development of drugs in the areas of human health and agricultural science. In summary, C4X Discovery's business model is focused on drug development and the application of elite technology to discover these drugs. The company aims to maximize the potential of its technology and enter additional partnerships to promote the development of new drugs for the treatment of diseases. With its diverse activities in drug and drug development and innovative technology, C4X Discovery predicts a promising future.

C4X Discovery Holdings maksab dividendi 0 GBP, mis jaotatakse väljamakse peale aasta jooksul.

Dividendi ei saa praegu C4X Discovery Holdings jaoks arvutada või ettevõte ei maksa dividende välja.

C4X Discovery Holdings ISIN on GB00BQQ2RV18.

C4X Discovery Holdings WKN on A12D8B.

C4X Discovery Holdings tähis on C4XD.L.

Viimase 12 kuu jooksul maksis C4X Discovery Holdings dividendi suuruses . See vastab ligikaudu dividenditootlusele. Järgneva 12 kuu jooksul maksab C4X Discovery Holdings tõenäoliselt dividendi summas 0 GBP.

C4X Discovery Holdings praegune dividenditootlus on .

C4X Discovery Holdings maksab kvartaalset dividendi. See makstakse välja kuudel .

C4X Discovery Holdings maksis viimase 0 aasta jooksul igal aastal dividendi.

Järgmise 12 kuu jooksul oodatakse dividende summas 0 GBP. See vastab dividenditootlusele 0 %.

C4X Discovery Holdings on liigitatud sektorisse 'Tervis'.

Viimase C4X Discovery Holdings dividendide saamiseks 17.8.2024 suuruses 0 GBP pidid sul olema aktsiaid portfellis enne eks-dividendi päeva 17.8.2024.

Viimane dividendimakse toimus 17.8.2024.

Aastal 2023 maksis C4X Discovery Holdings 0 GBP dividende.

C4X Discovery Holdings dividendid makstakse välja GBP.